Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

measurement of intestinal permeability

Phase 1

UUniversity of Maryland, Baltimore

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

PrematurityNot yet recruiting

PrematurityPhase 1

Not yet recruiting

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

Prematurity

NCT07667049

Clinical

Trials by Indication[1]

Prematurity1 trial

Gut Permeability and Microbiome in Very Low Birth Weight Preterm Neonates.

Not yet recruiting·UUniversity of Maryland, Baltimore·Phase 1·NCT07667049·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for measurement of intestinal permeability. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for measurement of intestinal permeability. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Maryland, Baltimore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: UUniversity of Maryland, Baltimore

Related News